Wiskott-Aldrich syndrome; An X-linked primary immunodeficiency disease with unique and characteristic features

Allergology International

Volumn 61, Issue 2, 2012, Pages 183-189

  Ariga, Tadashi ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Gene therapy; Hematopoietic stem cell transplantation; Immunodeficiency; WASP; Wiskott Aldrich syndrome

Indexed keywords

ACICLOVIR; ADENOSINE DEAMINASE; COTRIMOXAZOLE; IMMUNOGLOBULIN; THROMBOPOIETIN; WISKOTT ALDRICH SYNDROME PROTEIN;

ADENOSINE DEAMINASE DEFICIENCY; ARTICLE; AUTOIMMUNITY; BLEEDING; BLOODY DIARRHEA; BRAIN HEMORRHAGE; CLINICAL FEATURE; DIAGNOSTIC ERROR; DIAGNOSTIC PROCEDURE; ECZEMA; EPISTAXIS; EPSTEIN BARR VIRUS; FRAMESHIFT MUTATION; GENE IDENTIFICATION; GENE MUTATION; GENETIC ANALYSIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES VIRUS INFECTION; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE DEFICIENCY; IMMUNOPROPHYLAXIS; INDEL MUTATION; INFECTION SENSITIVITY; LEUKEMIA; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MISSENSE MUTATION; MYELODYSPLASTIC SYNDROME; NONSENSE MUTATION; OVERALL SURVIVAL; PHENOTYPIC VARIATION; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROTEIN STRUCTURE, FUNCTION AND VARIABILITY; PURPURA; SMALL PLATELET; SPLENECTOMY; SPLICING DEFECT; THROMBOCYTE; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; WISKOTT ALDRICH SYNDROME; X CHROMOSOME LINKED DISORDER; X LINKED SEVERE COMBINED IMMUNODEFICIENCY; X LINKED THROMBOCYTOPENIA;

EID: 84862666114     PISSN: 13238930     EISSN: 14401592     Source Type: Journal    
DOI: 10.2332/allergolint.11-RAI-0412     Document Type: Review

References (39)

1. Wiskott A. Familiärer, angeborener Morbus Werlhofii? Monatsschr Kinderheilkd 1937;68:212-6(in German).
2. Aldrich RA, Steinberg AG, Campbell DC. Pedigree demonstrating a sex-linked recessive condition characterized by draining ears, eczematoid dermatitis and bloody diarrhea. Pediatrics 1937;13:133-9.
3. Derry JM, Ochs HD, Francke U. Isolation of a novel gene mutated in Wiskott-Aldrich syndrome. Cell 1994;78:635-44.
4. Al-Herz W, Bousfiha A, Casanova J-L, et al. Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Society Expert Committee for Primary Immunodeficiency. Front Immun. In press.
5. Villa A, Notarangelo LD, Macchi P et al. X-linked thrombocytopenia and Wiskott-Aldrich syndrome are allelic diseases with mutations in the WASP gene. Nat Genet 1995; 9:414-7.
6. Ochs HD, Rosen FS. The Wiskott-Aldrich syndrome. In: Ochs HD, Smith CIE, Puck JM (eds). Primary Immunodeficiency Diseases: A Molecular and Genetic Approach. New York: Oxford University Press, 2007;454-69.
7. AlbertMH, Bittner TC, Nonoyama S et al. X-linked thrombocytopenia (XLT) due to WAS mutations: clinical characteristics, long-term outcome, and treatment options. Blood 2010;115:3231-8.
8. Devriendt K, Kim AS, Mathijs G et al. Constitutively activating mutation in WASP causes X linked severe congenital neutropenia. Nat Genet 2001;27:313-7.
9. Miki H, Miura K, Takenawa T. N-WASP, a novel actinpolymerizing protein, regulates the cortical cytoskeletal rearrangement in a PIP2-dependent manner downstream of tyrosine kinases. EMBO J 1996;15:5326-35.
10. Miki H, Suetsugu S, Takenawa T. WAVE, a novel WASPfamily protein involved in actin reorganization induced by Rac. EMBO J 1998;17:6932-41.
11. de la Fuente MA, Sasahara Y, Ramesh N et al. WIP is achaperone for Wiskott-Aldrich syndrome protein (WASP). Proc Natl Acad Sci U S A 2007;104:926-31.
12. Imai K, Morio T, Zhu Y et al. Clinical course of patients with WASP gene mutations. Blood 2004;103:456-64.
13. Jin Y, Mazza C, Christie JR et al. Mutations of the Wiskott-Aldrich Syndrome Protein (WASP): hotspots, effect on transcription, and translation and phenotype_ genotype correlation. Blood 2004;104:4010-9.
14. Lutskiy MI, Rosen FS, Remold-O'Donnell E. Genotypeproteotype linkage in Wiskott-Aldrich syndrome. J Immunol 2005;175:1329-36.
15. Albert MH, Bittner TC, Nonoyama S et al. X-linked thrombocytopenia (XLT) due to WAS mutations: clinical characteristics, long-term outcome, and treatment options. Blood 2010;115:3231-8.
16. Ancliff PJ, Blundell MP, Cory GO et al. Two novel activating mutations in the Wiskott-Aldrich syndrome protein result in congenital neutropenia. Blood 2006;108:2182-9.
17. Rawlings SL, Crooks GM, Bockstoce D, Barsky LW, Parkman R, Weinberg KI. Spontaneous apoptosis in lymphocytes from patients with Wiskott-Aldrich Syndrome: correlation of accelerated cell death and attenuated Bcl-2 expression. Blood 1999;94:3872-82.
18. Kajiwara M, Nonoyama S, Eguchi M et al. WASP in involved in proliferation and differentiation of human haematopoietic progenitors in vitro. Br J Haematol 1999;107: 254-62.
19. Burns S, Cory GO, Vainchenker W, Thrasher AJ. Mechanisims of WASp-mediated hematologic and immunologic diseases. Blood 2004;104:3454-62.
20. Bienemann K, Gudowius S, Neihues T. Topical tacrolimus is effective against eczema in Wiskott-Aldrich syndrome (WAS). Acta Paediatr 2007;96:312-4.
21. Trifari S, Sitia G, Aiuti A et al. Defective Th1 cytokine gene transcription in CD4+ and CD8+ T cells from Wiskott-Aldrich syndrome patients. J Immunol 2006;177: 7451-61.
22. Dupuis-Girod S, Medioni J, Haddad E et al. Autoimmunity in Wiskott-Aldrich syndrome: risk factors, clinical features, and outcome in a single-center cohort of 55 patients. Pediatr 2003;111:e622-7.
23. Sullivan KE, Mullen CA, Blaese RM, Winkelstein JA. A multi-institutional survey of Wiskott-Aldrich syndrome. J Pediatr 1994;125:876-85.
24. Ariga T, Takahashi Y, Watanabe T et al. Membranous glomerulonephritis in Wiskott-Aldrich syndrome. Acta Paediatr Jpn 1986;28:226-31.
25. Maillard MH, Cotta-de-Almeida V, Takeshima F et al. The Wiskott-Aldrich syndrome protein is required for the function of CD4(+)CD25(+)Foxp3(+) regulatory T cells. J Exp Med 2007;204:381-91.
26. Nakanishi M, Kikuta H, Tomizawa K et al. Distinct clonotypic Epstein-Barr virus-induced fatal lymphoproliferative disorder in a patient with Wiskott-Aldrich syndrome. Cancer 1993;72:1376-81.
27. Shcherbina A, Cancotti F, Rosen FS, Remold-O'Donnell E. High incidence of lymphoma in a subgroup of Wiskott-Aldrich syndrome patients. Br J Haematol 2003;121:529-30.
28. Yamada M, Ohtsu M, Kobayashi I et al. Flow cytometric analysis of Wiskott-Aldrich syndrome (WAS) protein in lymphocytes from WAS patients and their familial carriers. Blood 1999;93:756-7.
29. Yamada M, Ariga T, Kawamura N et al. Determination of carrier status for the Wiskott-Aldrich syndrome by flow cytometric analysis of Wiskott-Aldrich syndrome protein expression in peripheral blood mononuclear cells. J Immunol 2000;165:1119-22.
30. Ariga T, Nakajima M, Yoshida J et al. Confirming or excluding the diagnosis of Wiskott-Aldrich syndrome in children with thrombocytopenia of an unknown etiology. J Pediatr Hematol Oncol 2004;26:435-40.
31. Hirshhorn R. In vivo reversion to normal of inherited mutations in humans. J Med Genet 2003;40:721-8.
32. Ariga T, Oda N, Yamaguchi K et al. T cell lines from 2 patients with adenosine deaminase (ADA) deficiency showed the restoration of ADA activity resulted from the reversion of an inherited mutation. Blood 2001;97:2896-9.
33. Ariga T, Kondoh T, Yamaguchi K et al. Spontaneous in vivo reversion of an inherited mutation in the Wiskott-Aldrich syndrome. J Immunol 2001;166:5245-9.
34. Ariga T, Yamada M, Sakiyama Y, Tatsuzawa O. A case of Wiskott-Aldrich Syndrome with dual mutations in exon 10 of the WASP gene: An additional de novo one-base insertion, which restores frame shift due to an inherent onebase deletion, detected in the major population of the patient's peripheral blood lymphocytes. Blood 1998;92:699-701.
35. Moratto D, Giliani S, Bonfim C et al. Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative study. Blood 2011;118:1675-84.
36. Kobayashi R, Ariga T, Nonoyama S et al. Outcome in patients with Wiskott-Aldrich syndrome following stem cell transplantation: an analysis of 57 patients in Japan. Br J Haematol 2006;135:362-6.
37. Yamaguchi K, Ariga T, Yamada M et al. Mixed chimera status of 12 patients with Wiskott-Aldrich syndrome (WAS) after hematopoietic stem cell transplantation; evaluation by flow cytometric analysis of intracellular WAS protein expression. Blood 2002;100:1208-14.
38. Boztug K, Schmidt M, Schwarzer A et al. Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N Engl J Med 2010;363:1918-27.
39. Fischer A, Hacein-Bey-Abina S, Cavazzana-Calvo M. Gene therapy for primary adaptive immune deficiencies. J Allergy Clin Immunol 2011;127:1356-9.